Pluripotent Stem Cell-Derived Cardiomyocytes as a Platform for Cell Therapy Applications: Progress and Hurdles for Clinical Translation
Authors:
Open Access
- 1 July 2018
- journal article
- review article
- Published by Elsevier in Molecular Therapy
- Vol. 26 (7) , 1624-1634
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (R01 HL133272, R01 HL113006)
- American Heart Association (17MERIT33610009)
- California Institute of Regenerative Medicine (17SDG33660794, RT3-07798, DR2A-05394)
This publication has 130 references indexed in Scilit:
- Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured heartsNature, 2012
- Low Incidence of DNA Sequence Variation in Human Induced Pluripotent Stem Cells Generated by Nonintegrating Plasmid ExpressionCell Stem Cell, 2012
- Dantrolene rescues arrhythmogenic RYR2 defect in a patient‐specific stem cell model of catecholaminergic polymorphic ventricular tachycardiaEMBO Molecular Medicine, 2012
- Production of De Novo Cardiomyocytes: Human Pluripotent Stem Cell Differentiation and Direct ReprogrammingCell Stem Cell, 2012
- An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cellsNature Biotechnology, 2011
- Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutationEuropean Heart Journal, 2011
- Short-Term Immunosuppression Promotes Engraftment of Embryonic and Induced Pluripotent Stem CellsCell Stem Cell, 2011
- Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndromeNature, 2011
- Direct Reprogramming of Fibroblasts into Functional Cardiomyocytes by Defined FactorsCell, 2010
- Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenograftsProceedings of the National Academy of Sciences of the United States of America, 2008